Delray Beach Skin Cancer

In the 1980s, Superficial Radio Therapy was becoming a less popular option for keloid treatment due to the absence of any significant improvements in the technology, and equipment around the country was falling apart. Jump ahead 30 years or so, and this is no longer the case. Increasing awareness of available scar treatment, technological advancement in the sector, and increasingly appearance-conscious consumers are leading to significant growth in the SRT Therapy market. Thanks to Sensus Healthcare, SRT has become one of the most effective methods of treatment for excision keloid scars and non-melanoma skin cancers.

About Keloid Treatment with the SRT-100™

As skin cancer incidence continues to rise, and keloid scars continue to grow, it’s important to offer the best keloid treatment available to patients. This is both true around the United States and the rest of the world. Keloid removal normally involves several surgeries. This is due to the keloids growing back at the new incision sites in up to 90 percent-plus of cases. But, when SRT follows surgical removal, recurrence rates drop to as low as 10 percent. The SRT-100™ delivers a precise, calibrated dose of SRT Therapy. This radiation only goes skin deep. Thus, safely destroying the cells that form keloids and keeping the skin smooth while the incision heals.

This procedure can be performed right in your office, and each treatment session is painless for the patient. There is no need for anesthesia, cutting, or stitching, and no risk of infection continued scarring or bleeding. Patients will usually undergo a series of treatments depending on the condition of the incision site.

The SRT-100™ has FDA clearance and is perfect for private practices, hospitals, and multi-locale healthcare providers. If you’re interested in learning more about post-surgical keloid treatment by Sensus Healthcare’s SRT-100™, contact us today for more information. Give your patients another option.

 

**Original post date December 26, 2016. Updated March 27, 2020.